Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity

British Journal of Haematology

Volumn 181, Issue 3, 2018, Pages 413-417

  Lohse, Stefan ^a,e   Loew, Sebastian ^a   Kretschmer, Anna ^a   Jansen, J H Marco ^b   Meyer, Saskia ^b   ten Broeke, Toine ^b   Rösner, Thies ^a   Dechant, Michael ^c   Derer, Stefanie ^a   Klausz, Katja ^a   Kellner, Christian ^a   Schwanbeck, Ralf ^a   French, Ruth R ^d   Tipton, Thomas R W ^d   Cragg, Mark S ^d   Schewe, Denis M ^a   Peipp, Matthias ^a   Leusen, Jeanette H W ^b   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Internal Medicine   (Germany)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

ADCC; antibody therapy; CD20; IgA antibody; myeloid effector cells

Indexed keywords

CD20 ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN A2; CD20 ANTIGEN; COMPLEMENT; IMMUNOGLOBULIN A; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; B-CELL LEUKEMIA CELL LINE; BAGG ALBINO MOUSE; BONE MARROW CELL; CHROMIUM RELEASE ASSAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LETTER; MONONUCLEAR CELL; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAMOS CELL LINE; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG EFFECT; IMMUNOLOGY; PATHOLOGY; PROLYMPHOCYTIC LEUKEMIA;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CHO CELLS; COMPLEMENT SYSTEM PROTEINS; CRICETULUS; HUMANS; IMMUNOGLOBULIN A; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MYELOID CELLS;

EID: 85018721410     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14624     Document Type: Letter

References (10)

1. Beers, S.A., Chan, C.H., James, S., French, R.R., Attfield, K.E., Brennan, C.M., Ahuja, A., Shlomchik, M.J., Cragg, M.S. & Glennie, M.J. (2008) Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood, 112, 4170–4177.
2. Boross, P., Lohse, S., Nederend, M., Jansen, J.H., van Tetering, G., Dechant, M., Peipp, M., Royle, L., Liew, L.P., Boon, L., van Rooijen, N., Bleeker, W.K., Parren, P.W., van de Winkel, J.G., Valerius, T. & Leusen, J.H. (2013) IgA EGFR antibodies mediate tumour killing in vivo. EMBO Molecular Medicine, 5, 1213–1226.
3. Engelberts, P.J., Voorhorst, M., Schuurman, J., van Meerten, T., Bakker, J.M., Vink, T., Mackus, W.J.M., Breij, E.C.W., Derer, S., Valerius, T., van de Winkel, J., Parren, P.W.H.I. & Beurskens, F.J. (2016) Type I CD20 antibodies recruit the B-cell receptor for complement-dependent lysis of malignant B cells. The Journal of Immunology, 197, 4829–4837.
4. Könitzer, J.D., Sieron, A., Wacker, A. & Enenkel, B. (2015) Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS ONE, 10, e0145633.
5. Lohse, S., Meyer, S., Meulenbroek, L.A., Jansen, J.H., Nederend, M., Kretschmer, A., Klausz, K., Moginger, U., Derer, S., Rosner, T., Kellner, C., Schewe, D., Sondermann, P., Tiwari, S., Kolarich, D., Peipp, M., Leusen, J.H. & Valerius, T. (2016) An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Research, 76, 403–417.
6. Maloney, D.G. (2012) Anti-CD20 antibody therapy for B-cell lymphomas. The New England Journal of Medicine, 366, 2008–2016.
7. Pascal, V., Laffleur, B., Debin, A., Cuvillier, A., van Egmond, M., Drocourt, D., Imbertie, L., Pangault, C., Tarte, K., Tiraby, G. & Cogne, M. (2012) Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica, 97, 1686–1694.
8. Stockmeyer, B., Dechant, M., van Egmond, M., Tutt, A.L., Sundarapandiyan, K., Graziano, R.F., Repp, R., Kalden, J.R., Gramatzki, M., Glennie, M.J., van de Winkel, J.G. & Valerius, T. (2000) Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. The Journal of Immunology, 165, 5954–5961.
9. Taylor, R.P. & Lindorfer, M.A. (2015) Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood, 125, 762–766.
10. Weiner, G.J. (2010) Rituximab: mechanism of action. Seminars in Hematology, 47, 115–123.